This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
by Zacks Equity Research
Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of +88.24% and +24.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
by Zacks Equity Research
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -16.67% and 12.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
by Zacks Equity Research
Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
by Zacks Equity Research
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 28.57% and 1.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
by Zacks Equity Research
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
by Zacks Equity Research
Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -7.14% and 6.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -8.33% and 6.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.